Product How it works Pricing Blog FAQ About Contact
Voyager Therapeutics

Voyager Therapeutics (NASDAQ: VYGR) net income

Voyager Therapeutics reported a net loss of $119.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $65.0m. Earnings per share were −$2.04.

Voyager Therapeutics's best year of the last 10 was fiscal 2023. It reported a loss in 8 of those 10 years.

Net income, in millions of US dollars-40.22016-70.72017-88.32018-43.6201936.72020-71.22021-46.42022132.32023-65.02024-119.72025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$119.7m—−296.5%−$2.04
2024−$65.0m−149.1%−81.3%−$1.13
2023$132.3m—52.9%$3.08
2022−$46.4m—−113.4%−$1.21
2021−$71.2m−293.8%−190.3%−$1.89
2020$36.7m—21.5%$0.99
2019−$43.6m—−41.8%−$1.21
2018−$88.3m—−1,158.8%−$2.75
2017−$70.7m—−697.6%—
2016−$40.2m—−282.7%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Voyager Therapeutics net income compared with its sector

By net income for its latest fiscal year, Voyager Therapeutics ranks 354th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Voyager Therapeutics, −296.5%.

RankCompanyNet incomeNet margin
352ndKorro Bio−$117.3m−1,834.5%
353rdSavara−$118.8m—
354thVoyager Therapeutics−$119.7m−296.5%
355thTYRA Biosciences−$119.9m—
356thAcumen Pharmaceuticals−$121.3m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Voyager Therapeutics

How much did Voyager Therapeutics earn in fiscal 2025?
Voyager Therapeutics reported a net loss of $119.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $65.0m.
What are the earnings per share of Voyager Therapeutics?
They were −$2.04 in fiscal 2025, compared with −$1.13 in fiscal 2024.
What was the most profitable year for Voyager Therapeutics?
Of its last 10 fiscal years, fiscal 2023, with $132.3m.
Where does Voyager Therapeutics rank in its sector by net income?
It ranks 354th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Voyager Therapeutics come from?
From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Voyager Therapeutics: the Voyager Therapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.